Check-Cap Ltd. (CHEK)
| Market Cap | 4.46M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -17.57M |
| Shares Out | 5.85M |
| EPS (ttm) | -3.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,605 |
| Open | 0.760 |
| Previous Close | 0.761 |
| Day's Range | 0.760 - 0.800 |
| 52-Week Range | 0.760 - 3.520 |
| Beta | 0.18 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Dec 3, 2024 |
About CHEK
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient’s back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application tha... [Read more]
Financial Performance
Financial StatementsNews
Nobul AI Corp and Check-Cap Ltd Enter into Definitive Business Combination Agreement
Proposed business combination to create a North American technology company with an AI-driven fintech marketplace. Combined company to apply for listing on Nasdaq and TSX TORONTO , March 25, 2024 /PRN...
SYMETRYX COMMENTS ON SUCCESSFUL CAMPAIGN AT CHECK-CAP LTD
TORONTO , Dec. 22, 2023 /PRNewswire/ - Symetryx Corporation ("Symetryx"), a Canadian venture company, is pleased to announce that the shareholders of Check-Cap Ltd. (NASDAQ: CHEK) voted overwhelmingly...
CHECK- CAP BOARD MEMBER'S STATEMENT ON THE STAND SUGGESTS A POTENTIAL CONFLICT OF INTEREST WITH KEYSTONE DENTAL
SYMETRYX RECOMMENDS VOTING AGAINST THE KEYSTONE DENTAL MERGER SYMETRYX RECOMMENDS VOTING FOR THEIR QUALIFIED INDEPENDENT BOARD NOMINEES TIME IS SHORT - THE VOTE DEADLINE IS 11:59 pm EST THURSDAY DECEM...
CITING THE MANY FDA ADVERSE EFFECTS TO KEYSTONE DENTAL - CHECK-CAP FOUNDER STRONGLY RECOMMENDS VOTING AGAINST THE KEYSTONE DENTAL MERGER ALSO RECOMMENDS VOTING FOR THE SYMETRYX BOARD NOMINEES
TORONTO , Dec. 8, 2023 /PRNewswire/ - Further to its news release of November 28, 2023, Symetryx continues to urge its fellow Check-Cap Ltd. ("Check-Cap") (NASDAQ: CHEK) shareholders to VOTE AGAINST ...
CHECK-CAP FOUNDER STRONGLY RECOMMENDS VOTING AGAINST THE KEYSTONE DENTAL MERGER AND FOR THE SYMETRYX BOARD OF DIRECTORS NOMINEES
TORONTO , Dec. 5, 2023 /PRNewswire/ - Today, Symetryx Corporation ("Symetryx") once again encourages our fellow shareholders of Check-Cap Ltd. ("Check-Cap") (NASDAQ: CHEK) to review the news release i...
Symetryx Today Issues Open Letter to Shareholders In Regard to the Upcoming Annual General Meeting
Recommends Fellow Shareholders Vote AGAINST Keystone Transaction & the Check-Cap Board Nominees - Further Recommends a Vote FOR the Symetryx Slate of Director Candidates Cites Unrealistic and Aggressi...
Keystone Dental Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Q3 revenue increased 18.9% year-over-year to $16.8M, including $11.9M from the U.S. Check-Cap shareholders to vote on proposed Business Combination Agreement with Keystone Dental at Annual General Mee...
Check-Cap Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Check-Cap shareholders to vote on proposed Business Combination Agreement with Keystone Dental at Annual General Meeting on Monday, December 18 th ISFIYA, Israel , Nov. 27, 2023 /PRNewswire/ -- Check...
Keystone Dental Holdings and Check-Cap Ltd Enter into Definitive Business Combination Agreement
Proposed business combination to create a Nasdaq-listed medical device company focused on advancing the commercial execution and market development of Keystone's comprehensive portfolio of implants, a...
Check-Cap Reports Second Quarter 2023 Financial Results
ISFIYA, Israel, Aug. 4, 2023 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), today announced financial results for the second quarter and six months ended June 30, 2023.
SYMETRYX CORP INCREASES NON-BINDING OFFER TO ACQUIRE CHECK-CAP TO $4.60 PER SHARE
TORONTO, ON , July 25, 2023 /PRNewswire/ - Today, Symetryx Corporation ("Symetryx") announced an increase in price per share for our non-binding proposal to acquire common shares of Check-Cap LTD (NAS...
Check-Cap Announces Review of Strategic Alternatives and Reduction in Workforce
ISFIYA, Israel , June 6, 2023 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) today announced that following a review of its business, resources and capabilities, it is ex...
Check-Cap Reports First Quarter 2023 Financial Results
ISFIYA, Israel , May 11, 2023 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first...
Check-Cap Reports Fourth Quarter and Full Year 2022 Financial Results
ISFIYA, Israel , March 31, 2023 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of...
Check-Cap Issues an Update to Shareholders
ISFIYA, Israel , March 21, 2023 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of...
Check-Cap Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
ISFIYA, Israel , Nov. 30, 2022 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of ...
Check-Cap Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
ISFIYA, Israel , Aug. 31, 2022 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of ...
Check-Cap Ltd. (NASDAQ: CHEK) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement
ISFIYA, Israel , June 23, 2022 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of ...
Check-Cap Reports First Quarter 2022 Financial Results and Corporate Update
Company initiated first part of its U.S. pivotal study in early May 2022 ISFIYA, Israel , June 1, 2022 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a ...
Check-Cap Announces Initiation of the U.S. Pivotal Trial
ISFIYA, Israel , May 11, 2022 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-...
Check-Cap Reports Fourth Quarter and Full Year 2021 Financial Results
Company anticipates initiation of the first part of its U.S. pivotal study in April 2022 ISFIYA, Israel , April 7, 2022 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (N...
Check-Cap Ltd. Announces $10 Million Registered Direct Offering
ISFIYA, Israel, March 1, 2022 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C...
FDA Gives Green To Check-Cap's Pivotal Study For Capsule-Based Colorectal Cancer Screening Test
The FDA has approved Check-Cap Ltd's (NASDAQ: CHEK) amended Investigational Device Exemption (IDE) application to initiate the U.S. pivotal study of C-Scan. The U.S. pivotal study consists of two part...
Check-Cap Announces FDA Approval of Amended IDE Application for Pivotal Study of C-Scan
ISFIYA, Israel, Feb. 7, 2022 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-...
Check-Cap Issues Letter to Shareholders
ISFIYA, Israel, Jan. 5, 2022 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-...